NSCLC: Cemiplimab plus Chemo auch bei niedriger PD-L1-Expression wirksam
Crossref DOI link: https://doi.org/10.1007/s15015-024-3740-6
Published Online: 2024-02-02
Published Print: 2024-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Özgör, Lamia
Text and Data Mining valid from 2024-02-01
Version of Record valid from 2024-02-01
Article History
First Online: 2 February 2024
Free to read: This content has been made available to all.